Trials that use: Kaplan-Meier estimation
New to this method? Read the tutorial →
343 results
- ABCSG-16Complete statistical analysis of ABCSG-16, the randomized phase 3 trial comparing 2 versus 5 years of additional anastrozole after 5 years of adjuvant endocrine therapy in breast cancer, including time-to-event endpoints, hazard…
- ABCSG-18Independent statistical analysis of ABCSG-18, a randomized phase 3 trial of denosumab in patients with breast cancer receiving aromatase inhibitor therapy, including trial design, fracture, bone mineral density, disease-free survival, bone metastases-free…
- ACCELERATEComplete statistical analysis of ACCELERATE (NCT01687998), a randomized phase 3 study of evacetrapib versus placebo in high-risk vascular disease, including trial design, composite cardiovascular endpoints, Cox modeling, ANOVA, confidence intervals, p-values, and…
- ACTG A5279Independent statistical analysis of ACTG A5279 (NCT01404312), a randomized phase 3 trial comparing a rifapentine-plus-isoniazid regimen with an isoniazid regimen for tuberculosis prevention in people with HIV.
- ACTT-2Independent statistical analysis of ACTT-2, the randomized phase 3 trial of remdesivir plus baricitinib versus remdesivir plus placebo in COVID-19, including time-to-recovery, ordinal-scale, and safety analyses.
- ACTT-3Independent statistical analysis of ACTT-3, the phase 3 randomized trial of remdesivir plus interferon beta-1a versus remdesivir plus placebo in COVID-19, including time-to-recovery, subgroup hazard ratios, safety, and statistical interpretation.
- ADAURAIndependent statistical analysis of the ADAURA phase 3 trial of AZD9291 versus placebo after complete tumour resection in stage IB-IIIA non-small cell lung carcinoma, including disease-free survival, overall survival, trial design, methodology,…
- ADRIATICIndependent statistical analysis of the phase 3 ADRIATIC trial of durvalumab, tremelimumab, and placebo in limited-stage small-cell lung cancer after concurrent chemoradiation, including randomized design, time-to-event endpoints, hazard ratios, confidence intervals, and…
- AFFIRMComplete statistical analysis of the AFFIRM phase 3 trial of enzalutamide versus placebo in patients with castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy, including overall survival, secondary time-to-event endpoints, response measures,…
- AGO-OVAR 12Independent statistical analysis of AGO-OVAR 12 (NCT01015118), a randomized phase 3 trial of nintedanib or placebo with paclitaxel and carboplatin in first-line ovarian cancer, including progression-free survival, overall survival, response, quality of…
- AIM-HIGHIndependent statistical analysis of AIM-HIGH, the randomized phase 3 trial of extended-release niacin plus simvastatin versus placebo plus simvastatin for prevention of vascular events, including its time-to-event endpoints, Cox model, hazard ratios,…
- ALEXIndependent statistical analysis of the phase 3 ALEX trial comparing alectinib with crizotinib in treatment-naive ALK-positive advanced non-small cell lung cancer, including progression-free survival, CNS progression, overall survival, response, quality-of-life endpoints, and…
- ALLIANCE A041202Independent statistical analysis of ALLIANCE A041202, a randomized phase 3 trial comparing rituximab and bendamustine hydrochloride, ibrutinib, or ibrutinib plus rituximab in older patients with previously untreated chronic lymphocytic leukemia.
- ALTTOIndependent statistical analysis of the phase 3 ALTTO trial of lapatinib and trastuzumab in breast neoplasms, covering randomized trial design, disease-free survival, overall survival, recurrence endpoints, safety, and time-to-event methodology.
- AMBITIONIndependent statistical analysis of the AMBITION phase 3 trial of first-line ambrisentan and tadalafil combination therapy in pulmonary arterial hypertension, including time-to-event analysis, secondary endpoints, statistical methodology, safety, and interpretation.
- APACTIndependent statistical analysis of APACT, the randomized phase 3 trial of nab-paclitaxel and gemcitabine versus gemcitabine alone as adjuvant therapy for patients with resected pancreatic cancer.
- APHINITYAn independent statistical analysis of APHINITY, the randomized phase 3 trial of pertuzumab added to trastuzumab and chemotherapy as adjuvant therapy in participants with HER2-positive primary breast cancer.
- APPRAISE-2Independent statistical analysis of APPRAISE-2, the randomized phase 3 trial of apixaban versus placebo in acute coronary syndrome, including time-to-event endpoints, Cox models, hazard ratios, confidence intervals, p-values, and safety results.
- ARAMISIndependent statistical analysis of the phase 3 ARAMIS trial of darolutamide versus placebo in men with high-risk non-metastatic castration-resistant prostate cancer, including metastasis-free survival, overall survival, time-to-event methods, and statistical interpretation.
- ARASENSIndependent statistical analysis of ARASENS, the randomized phase 3 trial of darolutamide plus standard androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer, including time-to-event methodology, reported hazard ratios, confidence intervals,…
- ARCHER 1050Independent statistical analysis of ARCHER 1050, the randomized phase 3 trial of dacomitinib versus gefitinib in first-line advanced NSCLC with EGFR-activating mutations, including PFS, overall survival, response, statistical methodology, and interpretation.
- ARCHESComplete statistical analysis of the ARCHES phase 3 trial of enzalutamide plus androgen deprivation therapy versus placebo plus ADT in metastatic hormone sensitive prostate cancer, including rPFS, overall survival, secondary endpoints, statistical…
- ARIEL3Independent statistical analysis of the phase 3 ARIEL3 trial of rucaparib as switch maintenance after platinum in relapsed high-grade serous or endometrioid ovarian cancer, including trial design, progression-free survival, Cox modeling, hazard…
- ARIEL4Independent statistical analysis of ARIEL4, a randomized phase 3 trial of rucaparib versus chemotherapy in patients with BRCA-mutant ovarian, fallopian tube, or primary peritoneal cancer, including time-to-event endpoints, Cox models, hazard ratios,…
- ARISTOTLEIndependent statistical analysis of ARISTOTLE (NCT00412984), including trial design, time-to-event endpoints, Cox proportional-hazards methodology, hazard ratios, confidence intervals, safety results, and statistical interpretation.
- ARTEMIS-IPFIndependent statistical analysis of ARTEMIS-IPF, the randomized phase 3 trial of ambrisentan versus placebo in idiopathic pulmonary fibrosis, including its time-to-event endpoint, hazard ratio, secondary analyses, statistical methods, and interpretation.
- ASCENTIndependent statistical analysis of ASCENT, a randomized phase 3 trial of sacituzumab govitecan versus Treatment of Physician's Choice in participants with refractory or relapsed metastatic triple-negative breast cancer.
- ASPECCTIndependent statistical analysis of ASPECCT, the randomized phase 3 comparison of panitumumab and cetuximab in patients with KRAS wild-type metastatic colorectal cancer, including non-inferiority analysis, hazard ratios, response, patient-reported outcomes, and safety.
- ASSUREIndependent statistical analysis of the ASSURE phase 3 trial of sunitinib malate or sorafenib tosylate in patients with kidney cancer removed by surgery, including disease-free survival, overall survival, statistical methodology, interpretation, and…
- ATLASIndependent statistical analysis of the ATLAS phase 3 trial comparing bevacizumab plus erlotinib with bevacizumab plus placebo for first-line treatment of non-small cell lung cancer, including progression-free survival, overall survival, trial design,…
- ATMOSPHEREIndependent statistical analysis of the ATMOSPHERE phase 3 trial of aliskiren and aliskiren/enalapril in chronic heart failure, including trial design, time-to-event endpoints, Cox modeling, non-inferiority, superiority, safety, and interpretation.
- AUGMENTIndependent statistical analysis of the phase 3 AUGMENT trial of rituximab plus lenalidomide versus rituximab plus placebo in relapsed or refractory indolent non-Hodgkin's lymphoma, including progression-free survival, overall survival, response endpoints, statistical…
- AURA3Complete statistical analysis of AURA3, the randomized phase 3 trial of osimertinib versus platinum-based doublet chemotherapy in locally advanced or metastatic non-small cell lung cancer, including endpoints, statistical methods, efficacy results, safety,…
- AURELIAIndependent statistical analysis of AURELIA, the randomized phase 3 trial of bevacizumab added to chemotherapy in patients with platinum-resistant ovarian cancer, including progression-free survival, response, overall survival, quality of life, statistical methodology,…
- AVERROESComplete statistical analysis of AVERROES, the randomized phase 3 study of apixaban versus acetylsalicylic acid in patients with atrial fibrillation, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, safety, and statistical…
- AXISIndependent statistical analysis of the phase 3 AXIS trial of axitinib versus sorafenib in metastatic renal cell cancer, including progression-free survival, overall survival, objective response rate, statistical methods, and interpretation.
- BARI 2DIndependent statistical analysis of BARI 2D, a randomized phase 3 factorial trial comparing revascularization with medical therapy and insulin-sensitizing with insulin-providing glycemic strategies, including five-year all-cause mortality and death, myocardial infarction, or…
- BEAUTIFULIndependent statistical analysis of the phase 3 BEAUTIFUL trial of ivabradine versus placebo in patients with stable coronary artery disease and left ventricular systolic dysfunction, including its composite primary endpoint, time-to-event methods,…
- BELINDAIndependent statistical analysis of the BELINDA phase 3 trial of tisagenlecleucel in adult patients with aggressive B-cell non-Hodgkin lymphoma, including trial design, event-free survival methodology, hazard ratio interpretation, confidence intervals, and statistical…
- BELLE-2Independent statistical analysis of the BELLE-2 phase 3 trial of BKM120 plus fulvestrant versus placebo plus fulvestrant in postmenopausal patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer refractory to…
- BELLE-3Independent statistical analysis of BELLE-3, a randomized phase 3 study of BKM120 with fulvestrant versus placebo with fulvestrant in patients with HR+, HER2-, AI-treated locally advanced or metastatic breast cancer who progressed…
- BOLERO-2Independent statistical analysis of BOLERO-2 (NCT00863655), a randomized phase 3 trial of everolimus plus exemestane versus placebo plus exemestane in postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer…
- BOLERO-3Independent statistical analysis of BOLERO-3, a randomized phase 3 trial of everolimus plus trastuzumab and vinorelbine versus placebo plus trastuzumab and vinorelbine in HER2/Neu-positive locally advanced or metastatic breast cancer.
- BOLERO-6Independent statistical analysis of the BOLERO-6 phase 2 trial of everolimus plus exemestane versus everolimus alone and capecitabine in advanced breast cancer, including time-to-event methods, non-inferiority interpretation, quality-of-life analyses, and safety.
- BOSTONIndependent statistical analysis of the phase 3 BOSTON trial of selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in multiple myeloma, including PFS, response, overall survival, safety, and statistical methodology.
- BREAKWATERIndependent statistical analysis of the BREAKWATER phase 3 trial of encorafenib plus cetuximab with or without chemotherapy in previously untreated metastatic colorectal cancer, including trial design, primary endpoints, hazard ratios, odds ratios,…
- BRIM-3Independent statistical analysis of the randomized phase 3 BRIM-3 trial of vemurafenib versus dacarbazine in previously untreated patients with metastatic melanoma, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank testing, and interpretation.
- CALLAIndependent statistical analysis of the CALLA phase 3 trial of durvalumab with chemoradiotherapy in women with locally advanced cervical cancer, including trial design, progression-free survival, overall survival, response endpoints, safety, and statistical…
- CAPItello-291Independent statistical analysis of CAPItello-291, a randomized phase 3 trial of capivasertib plus fulvestrant versus placebo plus fulvestrant in locally advanced or metastatic HR+/HER2- breast cancer, including progression-free survival and the trial's…
- CAPTIVATEIndependent statistical analysis of CAPTIVATE (NCT02910583), a randomized phase 2 trial of ibrutinib plus venetoclax in treatment-naive chronic lymphocytic leukemia and small lymphocytic lymphoma, including its primary endpoints, statistical methods, and interpretation.